PURE Bioscience Assists Disaster Relief in Haiti

Shipment Contains Enough IV-7 Water Purifier to Create 40 Million Gallons of Drinkable Water

SAN DIEGO, CA., January 25, 2010 – PURE Bioscience (NASDAQ: PURE) is sending 200,000 two-ounce bottles of IV-7 Ultimate Germ Defense™ silver dihydrogen citrate (SDC)-based water purifier to Project Hope for distribution in earthquake-ravaged areas of Haiti.  This quantity is enough to treat up to 40 million gallons of water.  San Diego-based CareFusion Corporation sponsored half of the donation.

The water purifier is in the form of a liquid concentrate, with just six drops needed to treat one gallon of water.  This convenient and portable solution can be rushed to areas of need more quickly and easily than containers of drinking water. 

The purifier is effective against a broad spectrum of bacteria, virus and fungus in a stable, non-toxic, tasteless, odorless and colorless solution.

Michael L. Krall, President and CEO of PURE Bioscience, said, “The earthquake victims in Haiti are in desperate need of water that is safe to drink.  Sending 200,000 bottles of water purifier to be distributed in areas hard hit by the earthquake will help ensure drinkable water for families until local water systems can be restored.”

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety.  Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds.  As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.  PURE is headquartered in El Cajon, California (San Diego metropolitan area).  Additional information on PURE is available at www.purebio.com. 

About CareFusion Corporation

CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® IV pumps, Pyxis® automated dispensing and patient identification systems, AVEA® and Pulmonetic Systems ventilation and respiratory products, ChloraPrep® products, MedMined™ services for infection surveillance, NeuroCare neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 15,000 people across its global operations. More information may be found at www.carefusion.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.